OX40-OX40L axis acts upstream of many important inflammatory pathways in autoimmune diseases. Inhibition of this pathway has been reported to lead to dampened Th2, Th17, Th22, and Th1 pathway activities in clinical trials and therefore has been proposed to underlie a broad spectrum of autoimmune diseases, such as atopic dermatitis. We constructed a biparatopic anti-OX40 antagonist antibody, BCG028. Results of preclinical studies are presented here, showing the best-in-class potential of BCG028.
